Real-world efficacy and safety of PD-1 inhibitors in patients with advanced esophageal squamous cell carcinoma: a single-center retrospective analysis
In this real-world cohort, PD-1 inhibitors demonstrated notable efficacy and manageable toxicity for ESCC. Younger patients, those with better performance status, and fewer metastases achieved better outcomes. Larger, multi-center studies with biomarker analysis are warranted to validate these findings.
Authors
- Xialu Zhang
- Yinghong Ren
- Lili Jia
- Yu Wang (ORCID: https://orcid.org/0000-0003-4764-4922)
- Xin Wang (ORCID: https://orcid.org/0000-0002-7296-9406)
- Qinqin Wang (ORCID: https://orcid.org/0000-0002-8860-2801)
- Yang Zhou (ORCID: https://orcid.org/0000-0002-2360-9076)
- Y. Zhao (ORCID: https://orcid.org/0000-0003-0494-6728)
- Minhan Zhai
Institutions
- Shangluo Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-29
- DOI
- https://doi.org/10.3389/fonc.2025.1658010
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00